(Q38378184)

English

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

scientific article published on 12 April 2017

Statements

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study (English)
Benoît Trottier
Jordan E Lake
Ken Logue
Cynthia Brinson
Lizette Santiago
Clare Brennan
Justin A Koteff
Brian Wynne
Judy Hopking
Catherine Granier
Michael Aboud
12 April 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit